Japanese pharmaceutical company Astellas Pharma is set to acquire Belgian drug discovery company Ogeda with an identical definitive agreement also signed.

"Private equity firm Apollo Capital has acquired an additional 7.5% stake in GLG Pharma, increasing its total stake in the target company to 11.33%."

The consideration for the acquisition is €500m ($532.5m) in an initial cash payment to acquire 100% equity in the target company at the closing of the agreement, and an additional €300m ($319.49m) upon attaining clinical development and regulatory milestones for a drug named fezolinetant.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The acquisition is expected to be completed in the second quarter of this year.

Private equity firm Apollo Capital has acquired an additional 7.5% stake in GLG Pharma, increasing its total stake in the target company to 11.33%.

GLG Pharma is a biotechnology company based in the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now